Anupam Rasayan eyes US, Europe pharma push after Bliss deal, one-third revenue from drugs

Anupam Rasayan India Ltd anticipates significant growth in its pharmaceutical segment over the next three years. The company expects pharmaceuticals to comprise one-third of overall revenue driven by the acquisition of Bliss GVS Pharma. Anupam's ability to offer integrated contract manufacturing services will facilitate its expansion in the US and Europe. Bliss currently operates at low capacity and presents opportunities...